On Friday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) was 0.71% up from the session before settling in for the closing price of $29.59. A 52-week range for AGIO has been $23.42 – $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 4.89% over the past five years. When this article was written, the company’s average yearly earnings per share was at -162.17%. With a float of $55.44 million, this company’s outstanding shares have now reached $57.89 million.
Let’s look at the performance matrix of the company that is accounted for 488 employees. In terms of profitability, gross margin is 83.22%, operating margin of -1188.86%, and the pretax margin is 1917.72%.
Agios Pharmaceuticals Inc (AGIO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Agios Pharmaceuticals Inc stocks. The insider ownership of Agios Pharmaceuticals Inc is 4.27%, while institutional ownership is 105.63%. The most recent insider transaction that took place on Apr 10 ’25, was worth 194,172. In this transaction Director of this company sold 7,497 shares at a rate of $25.90, taking the stock ownership to the 149,220 shares. Before that another transaction happened on Apr 08 ’25, when Company’s Director proposed sale 7,497 for $25.90, making the entire transaction worth $194,172.
Agios Pharmaceuticals Inc (AGIO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -162.17% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
You can see what Agios Pharmaceuticals Inc (AGIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.29, a number that is poised to hit -1.81 in the next quarter and is forecasted to reach -6.63 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals Inc (NASDAQ: AGIO) saw its 5-day average volume 0.5 million, a negative change from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 78.65%. Additionally, its Average True Range was 1.29.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 50.04%, which indicates a significant decrease from 79.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.46% in the past 14 days, which was lower than the 45.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.97, while its 200-day Moving Average is $38.99. Nevertheless, the first resistance level for the watch stands at $30.10 in the near term. At $30.39, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.92. If the price goes on to break the first support level at $29.28, it is likely to go to the next support level at $28.75. Assuming the price breaks the second support level, the third support level stands at $28.46.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are 57,915K outstanding shares of the company, which has a market capitalization of 1.73 billion. As of now, sales total 36,500 K while income totals 673,730 K. Its latest quarter income was 8,730 K while its last quarter net income were -89,290 K.
